The International Congress on
Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM)
Andel’s Hotel, Berlin, Germany, September 8-11, 2011 |
|
| |
| Congress Presentations |
 |
|
|
|
|
Friday, September 9, 2011 |
|
|
Session 1: SCT in Myeloma and MDS
Autologous SCT as first line treatment?
|
Yes: J.L. Harousseau, France |
|
Allo SCT in elderly patients (>60 y) with MDS
|
|
|
Session 2: Relapse Prevention
Can we prevent relapse by novel conditioning regimen?
|
| |
Special Debate: Is there any place for the prophylactic collection of autologous stem cells for major radiation incidents?
Yes: A.S. Shimosaka, Japan |
|
|
|
|
Session 3: AML and CML
Indication for unrelated allo SCT in 1. CR AML
|
No: I. Yakoub-Agha, France |
|
Allogeneic SCT for CML after failure to 1. TKI
|
|
|
|
Session 4: Treatment and Prevention of Relapse
Second allo for relaps
Donor selection to prevent relapse
|
According to KIR typing: J. Miller, USA |
| |
| |
Session 5: Aplastic Anemia and Autoimmune Diseases
Autologous SCT for autoimmune diseas
|
Yes: D. Farge-Bancel, France |
|
|
|
|
Session 6: Refractory and Residual Leukemia
Allo SCT for refractory leukemia
Should all MRD positive patients receive allo SCT?
|
| |
|
Session 7: GvHD Prevention by T-Cell Modulation
Can Treg prevent GvHD without losing GvL?
|
Yes: M.F. Martelli, Italy |
|
Is photopheresis treatment of choice for cGvHD?
|
|
|
Saturday, September 10, 2011 |
|
|
Session 8: Cord Blood
Is double cord blood to be preferred to a single unit?
Should cord blood unit be selected according to HLA or cell-based?
|
Cell-based: E. Gluckman, France |
| |
|
|
Session 9: Myelofibrosis and Haploidentical Transplantation
Allo SCT for elderly myelofibrosis patients (>60 y)
Should haplo-SCT be performed with T-cell depletion?
|
Yes: R. Handgretinger, Germany |
|
|
|
|
|
Session 10: Donor Selection
Which is the donor of choice if no MUD is available?
|
Cord blood: W. Arcese, Italy |
|
Should we expand cord blood?
|
|
|
|
Novartis Satellite Symposium
Update and Perspectives on Iron Chelation and Immunotherapy in Transplantation
|
Pathophysiology of Acute GvHD: Innate Meets Adaptive Immunity: E. Holler, Regensburg |
|
|
Does Iron Chelation Improve Survival in SCT? H. Al-Ali, Leipzig |
|
|
Practical Aspects of an Iron Chelation Therapy in SCT: U. Platzbecker, Dresden |
| |
| |
Session 11: Cell and Gene Therapy
Is specific T-cell therapy targeting mHag useful?
|
No: M. Bornhäuser, Germany |
| Gene therapy for genetic diseases (SCID, FA, CGD)
|
|
|
Session 12: Lymphoma
Autologous SCT in FL
|
Yes: C. Gisselbrecht, France |
|
Transplantation for T-cell lymphoma
|
Pro auto: P. Reimer, Germany |
| |
|
|
Session 13: T-Cell Depletion and Mesenchymal Stroma Cells
T-cell depletion and T-cell add back
|
Yes: J.H.F Falkenburg, The Netherlands |
|
|
|
|
Session 14: Allogeneic SCT for Myeloma and Hodgkin's Disease
Is there a place for allo SCT in Hodgkin’s disease?
|
| |
Session 15: GvHD Prevention by Antibodies
GvHD prevention
|
Pro Alemtuzemab: S. Mackinnon, UK |
|
Is it possible to separate GvHD from GvL?
|
|
|
Sunday, September 11, 2011 |
|
Session 16: Improving Transplant Outcome in Multiple Myeloma
Should CR be target of therapy in MM?
| Yes: S.A. Giralt, USA |
|
| No: B. Barlogie, USA |
|
Should CR be target of therapy in MM?
| Pro consolidation: J. Blade, Spain |
| |
| |
Session 17: InfectionShould CMV infection post allo SCT be treated by cell-based therapy?
Is combined antifungal therapy more efficient than single agent therapy?
| No: G. Maschmeyer, Germany |
|
|
| |
Session 18: Fungal Resistance
Aspergillus resistance is only seen on the petri dish and not in the patient
|
Con: G. Maschmeyer, Germany |
| |
| |
Session 19: ALL and Intensity of Conditioning Regimen
Reduced or standard conditioning?
| Pro reduced: R. Storb, USA |
|
|
|
|
|
|
WebStudio.co.il